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Prompt control of heart rate is important for successful
treatment of supraventricular tachyarrhythmias early
after open heart surgery when sympathetic tone is high
and ventricular response rates may be rapid. Esmolol,
a new ultrashort-acting (9 minute half-life)beta-receptor
blocking agent, was given by continuous intravenous
infusion for up to 24 hours in 24 patients (21with isolated
coronary bypass surgery and 3 with valve replacement)
1 to 7 days after surgery. Atrial fibrillation was present
in 9 patients, atrial flutter in 2 and sinus tachycardia in
13. Eleven patients had received intravenous digoxin
(average dose 0.6 mg, average serum level 1.19 mg/loo
ml) before esmolol infusion without adequate control of
the supraventricular tachyarrhythmia. After a 1 minute
loading infusion of esmolol (500 ILg/kg per min), main-
tenance dose, titrated to heart rate and blood pressure
response, varied from 25 to 300 ILg/kg per min.
After esmolol administration, at an average dose of
139 ± 83 lLg/kg per min, mean heart rate decreased
Supraventricular tachyarrhythmias are common after oth-
erwise uncomplicated open heart surgery. Atrial fibrillation
or flutter occurs in approximately 25% of patients after
coronary bypass surgery (l,2) and is even more common
after valve replacement. Sinus tachycardia is also frequent
in the absence of hypovolemia, congestive heart failure,
hypotension, pericardial tamponade and fever. It is often
accompanied by hypertension and hyperdynamic cardio-
vascular function usually in a patient withdrawn from treat-
ment with long-term beta-adrenergic blocking agents just
before surgery (3,4). Unfortunately, the tachycardia and
associated hemodynamic embarrassment are particularly un-
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from 130 ± 15 to 99 ± 15 beats/min. Within 5 to
18 minutes after initiation of therapy, all patients had
achieved a 15% reduction in heart rate at a maintenance
dose of 150 lLg/kg per min or less. A 20% reduction in
heart rate was attained in 19 of the 24 patients, and
conversion to sinus rhythm occurred during esmolol in-
fusion in 5 of the 11 patients with atrial flutter or fi-
brillation. Transient asymptomatic hypotension «90/50
mm Hg) was seen in 13 patients, requiring cessation of
esmolol therapy in 2. Mild induration at the intravenous
site (eight patients) and nausea (two patients) did not
require interruption of therapy.
Thus, in postoperative supraventricular tachyar-
rhythmias, esmolol 1) is effective in rapidly controlling
heart rate for up to 24 hours; 2) may result in conversion
to sinus rhythm; and 3) is welltolerated but may produce
treatment-limiting hypotension in a small number of
patients.
(J Am Coil CardioI1985;5:1451-6)
wanted at a time when normal convalescence has already
placed great metabolic demands on the patient.
For this reason it is important that prompt and sustained
control of ventricular response rates be achieved. A rationale
for the unique benefits of beta-adrenergic blockade is the
demonstration of elevated serum catecholamine levels and
evidence suggesting that sympathetic nervous system activ-
ity is excessive in the patient early after cardiac surgery
(5-8). Thus, we studied the effects of esmolol, a new in-
travenous beta-adrenergic blocking agent with a half-life of
approximately 9 minutes, in a trial for control of heart rate
in patients with supraventricular tachyarrhythmia after car-
diac surgery.
Methods
Patients. Those eligible for esmolol administration in-
cluded adults who developed a supraventricular tachyar-
rhythmia with a ventricular response rate of 100 beats/min
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or greater in the early postoperative period after cardiac
surgery using cardiopulmonary bypass. A criterion for ex-
clusion was a blood pressure level less than 90/60 mm Hg.
Patients with significant pulmonary or renal insufficiency
(creatinine >2.0 mg/IOO ml), preoperative congestive heart
failure (New York Heart Association functional class III or
IV), a history of bronchospasm severe enough to preclude
use of a beta-adrenergic blocking agent, life-threatening
noncardiac disease or known malignancy were also ex-
cluded. None of the patients received other beta-adrenergic
blocking or calcium channel blocking agents before or dur-
ing the study for a period equal to two half-lives of the
agent in question. No other antiarrhythmic agents were added
during infusion of esmolol; however, such drugs were not
discontinued if patients were receiving them before the start
of the study and blood levels had stabilized. Eleven patients
had received intravenous digitalizing doses before esmolol
infusion without adequate clinical effect. Mean serum dig-
oxin level in these 11 patients was I. 19 ± 0.71 mg/100 ml
at the start of esmolol infusion.
Twenty-four patients ranging in age from 42 to 78 years
(mean 61 ± 11) met these criteria and were studied I to 7
days after coronary bypass surgery or valve replacement
surgery, or both. Although patients were eligible for treat-
ment at any time after surgery, none received esmolol until
24 hours after surgery. No patient had rapid atrial fibrillation
or flutter within 24 hours of surgery. Treatment with esmolol
was begun as early as 1 to 2 hours after arrhythmia onset,
but in many patients was delayed for up to 48 hours while
attempts were made to control heart rate with conventional
therapy using digoxin and verapamil. Sinus tachycardia was
often present from the time of rewarming, but a delay in
drug treatment was warranted to allow for spontaneous res-
olution and rule out a possible specific cardiac cause.
Twenty-one patients underwent isolated coronary bypass
surgery, arid three patients had one or more valves replaced
(mitral in two, aortic in three), including two patients who
had concomitant bypass surgery. On average, 3.5 grafts per
patient were inserted. The surgical technique employed a
bubble oxygenator with single cannulation for the patients
undergoing coronary bypass grafting. A double venous can-
nula technique for mitral valve replacement was utilized.
Moderate to profound systemic hypothermia and hyperka-
lemic, cold, multidose cardioplegia were used. The average
cardiopulmonary bypass duration was 130 ± 51 minutes;
the average cross-clamp time was 79 ± 33 minutes.
Tachyarrhythmias. Atrial fibrillation occurred in nine
patients, and atrial flutter occurred in two; these arrhythmias
appeared an average of 4 days after surgery. Three patients
had a preoperative history of intermittent atrial fibrillation.
Unexplained (primary) sinus tachycardia was present from
the time of surgery in 13 patients. Long-term oral beta-
adrenergic blocking therapy had been used in 6 of these 13
patients and 3 of the 11 patients with atrial fibrillation or
flutter.
After a patient was found suitable for study, informed
consent was obtained and a 30 minute period of continuous
electrocardiographic observation was begun to evaluate the
persistence of arrhythmia. During this time, a physical ex-
amination and 12 lead electrocardiogram were performed.
Treatment end points and drug administration. This
study was of the open label type, the end points of which
were: I) a 15% reduction in heart rate, or 2) conversion to
sinus rhythm. Esmolol for infusion was prepared by diluting
10 g of esmolol hydrochloride (supplied by American Crit-
ical Care as 10 ml ampules containing I g of drug each) in
900 ml of 5% dextrose in water. This resulted in a final
concentration of 10 mg/ml, which was infused using an
accurate volumetric infusion pump.
Titration period. The drug administration period con-
sisted of initial titration followed by maintenance infusion
and was terminated by a follow-up period. The titration
sequence began with a I minute loading infusion of 500
p,g/kg per min followed by the initial titration infusion of
50 p,g/kg per min for 4 minutes. At the end of 4 minutes,
the patient's vital signs were recorded, and if he or she had
not met the study end points, a repeat 500 p,g/kg per min
loading infusion was given, followed by a 4 minute infusion
at a dose level of 100 p,g/kg per min. Progressively higher
dose levels were used in sequence if needed, including 150,
200 and 250, up to a maximum of 300 p,glkg per min. Each
increase in dose level was preceded by a 500 p,g/kg per min
loading infusion. If the patient had achieved a 15% reduction
in heart rate, but a more optimal clinical response was de-
sired, a still higher dose level (up to 300 p,glkg per min)
could be chosen. After the first 20 patients had been studied,
the protocol was altered to allow for an initial titration in-
fusion of 25 p,g/kg per min. This altered protocol was used
in the last four patients, only one of whom remained at this
dose level because the study end points had been achieved.
Maintenance period. After selection of the proper dose
level by titration, the patient entered a maintenance period
of 24 hours or less. If there was loss of control of heart rate
during this period, the esmolol dose could be increased up
to a maximum of 300 p,g/kg per min provided that a loading
infusion preceded the change. The maintenance dose could
also be adjusted downward if needed. This adjustment was
most often made because of mild hypotension or excessive
reduction in heart rate, both of which commonly responded
to a lowering of the dose. During maintenance and follow-
up study, electrocardiograms and vital signs were monitored
and the patient was closely watched for signs of an adverse
reaction.
Follow-up period. After 24 hours (or sooner if an ad-
verse reaction occurred), administration of esmolol was dis-
continued and the patient entered the follow-up period. At
this time electrocardiographic monitoring was continued, a
repeat 12 lead electrocardiogram was obtained and repeat
physical examination was performed.
Atrialflutter orfibrillation versus sinus tachycardia. The
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Figure 1. Maximal esmolol maintenance dose required to achieve
desired clinical heart rate response.Results
study group included 11 patients with either atrial fibrillation
(9) or atrial flutter (2) as well as 13 patients with sinus
tachycardia. Special care was taken within the latter group
to rule out both cardiac and noncardiac causes of sinus
tachycardia that might result in a rapid heart rate as a com-
pensatory mechanism. It was believed that the augmented
heart rate was part of an overall hyperdynamic postoperative
cardiovascular state. Because of the inherent differences
between atrial arrhythmias and sinus tachycardia, their dif-
fering effects on cardiac pump function and possible dif-
ferences in etiology, patients with these two types of ar-
rhythmias were compared.
Statistics. All data are reported as mean ± SD. Statis-
tical analysis comparing patients with sinus tachycardia and
atrial fibrillation utilized the Mann-Whitney U test (9).
±24
±16
±38
±19±19±17
20 ±19
±7
±8 ±9 ±10 ±70- 0 ~3 ±o0 cr
"0 0
I , I I I , ,
BASELINE 50 100 150 200 250 300
n= 24 24 17 12 8 4 2
ug/kg/min
130
Figure 2. The dose-response of esmolol on heart rate and blood
pressure. Mean data ± SD are shown. RPM = beats/min; n =
number of patients.
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tically significant differences are present, the trend suggests
that pretreatment with digoxin allows a higher proportion
of patients to achieve a 15% heart rate reduction end point
at the same or smaller dose of esmolol. For example, after
pretreatment with digoxin, 9 (82%) of the 11 patients re-
sponded to 50 J,Lg/kg per min compared with 8 (62%) of 13
patients without digoxin. Digoxin pretreatment had been
Heart rate response. The heart rate decreased from an
average of 130 ± 15 to 99 ± 15 beats/min during esmolol
infusion. Within 5 to 18 minutes all 24 patients had achieved
a 15% reduction in heart rate at a maintenance dose of 150
J,Lg/kg per min or less. This occurred regardless of type of
rhythm (atrial fibrillation versus sinus tachycardia) or di-
goxin pretreatment. A 20% reduction in heart rate was at-
tained in 19 patients. In 5 of 11 patients with atrial fibril-
lation or flutter the arrhythmia was converted to sinus rhythm
during the infusion of esmolol. Heart rate decreased to a
level of 100 beats/min or less in 15 patients.
Dose response. Although the maintenance doses ranged
from 25 to 300 J,Lg/kg per min, all patients achieved a 15%
reduction in heart rate at a dose of 150 J,Lg/kg per min or
less. Eight patients were given a larger dose of esmolol in
an attempt to further control their heart rate response. Two
patients received the maximal dose of 300 J,Lg/kg per min.
Figure 1 shows the distribution of maximal doses in the 24
patients. The most common dose administered was 50 J,Lg/kg
per min and the mean dose administered was 139 ± 83
J,Lg/kg per min. The dose-response information in Figure 2
shows that the greatest proportional heart rate reduction
occurred at a low maintenance dose (50 J,Lg/kg per min).
However, certain patients were able to achieve a 15% re-
duction in heart rate only at 100 J,Lg/kg per min (four pa-
tients) or 150 J,Lg/kg per min (three patients). Doses of 200
J,Lg/kg per min or greater resulted in no additional decrease
in mean heart rate, conversion to sinus rhythm or clinically
important individual end points.
Effect of pretreatment with intravenous digoxin. In-
travenous digoxin (average dose 0.6 mg) had been given to
II patients (6 with atrial fibrillation, 2 with atrial flutter and
3 with sinus tachycardia). The effects of this pretreatment
on the dose-response relation noted with esmolo1were com-
pared. Figure 3 illustrates the proportion of patients achiev-
ing a 15% heart rate reduction at various esmolol doses with
and without pretreatment with digoxin. Although no statis-
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Figure 3. Response to esmolol with and without digoxin pre-
treatment.
given to four of the five patients with atrial fibrillation whose
arrhythmia was converted to sinus rhythm .
Comparison of esmolol response in atrial fibrillation
or flutter versus sinus tachycardia (Table 1). The mean
baseline heart rate was faster in patients with atrial fibril-
lation (143 ± 15 beats/min) than in patients with sinus
tachycardia (121 ± 7, P < 0.(01). Systolic blood pressure
was lower in those with atrial fibrillation (111 ± 10 mm
Hg) than in those with sinus tachycardia (136 ± 26 mm
Hg, p < 0.006), whereas the diastolic pressure was similar
in both groups (66 ± 6 versus 65 ± 8 mm Hg) . The percent
heart rate reduction with esmolol tended to be greater in
patients with atrial fibrillation ( - 29 ± II %) than in those
with sinus tachycardia (- 22 ± 5%, P = 0.05). This oc-
curred even though more patients with atrial fibrillation (5
of II) than with sinus tachycardia (3 of 13) achieved their
maximal heart rate reduction with the small maintenance
dose of 50 p,glkg per min. The average maintenance dose
o Individual dose response
o o.mJabve dose response
in patients with atrial fibrillation was 134 ± 92 p,glkg per
min compared with 142 ± 79 p,glkg per min in those with
sinus tachycardia. The percent reduction in systolic blood
pressure was similar (16 versus 17%), as was the reduction
in diastolic blood pressure (9 versus 6%).
Adverse effects. The most common side effect was hy-
potension ($90/50 mm Hg), which occurred in 13 patients
(7 of the 11 with atrial fibrillation and 6 of the 13with sinus
tachycardia ). This occurrence was related more to pretreat-
ment blood pressure levels than to specific dose level of
esmolol. In II patients , the hypotension was asymptomatic
and transient, correcting without changes in regimen (7 pa-
tients) or with intravenous fluid administration or a reduction
in the maintenance dose of esmolol, or both (4 patients).
In two patients, hypotension did not resolve even at the
smallest dose of esmolol (although both continued to have
adequate heart rate control at this dose) , necessitating dis-
continuation of therapy after 3.5 and 5.0 hours, respectively .
In these two patients, blood pressure normalized within 4
to 10 minutes.
In eight patients, a painless localized induration devel-
oped at the intravenous infusion site (usually located on the
inner aspect of the mid forearm ), beginning approximately
12 hours after the initiation of therapy. The area was slightly
red and swollen and disappeared within 24 hours after the
cessation of therapy. These changes were noted despite a
freshly inserted, well functioning plastic intravenous cannula.
Mild nausea without vomiting developed in two patients
being treated on the first and fifth postoperative day , re-
spect ively . Headaches were noted during therapy in two
patients, both of whom had headaches before initiation of
esmolol therapy. A diffuse , nonpruritic, erythematous, ma-
culopapular rash noted before the titration period in one
patient worsened somewhat during the first few hours of
esmolol administration, subsiding within 2 days after dis-
continuation of the drug.
One patient who experienced a particularly marked de-
crease in heart rate at a maintenance dose of 50 p,g/kg per
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Table 1. Effects of Esmolol in Patients With Atrial Fibrillation or Flutter and Sinus Tachycardia
Baseline Baseline Baseline
HR Esmolol SAP Esmolol OAP Esmolol
(beats/min) ~ (%) (mm Hg) ~(%) (mm Hg) ~ (%)
Atrial fibrillation or flutter
Mean 143 - 30 III -16 66 -9
SO 15 11 10 8 6 9
Range 123 to 170 - 18 to -52 103 to 138 -510-27 57 to 78 5 to - 26
p value 0.001 0.044 0.006 0.762 0.796 0.357
Sinus tachycardia
Mean 121 -22 136 -17 65 -6
SO 7 5 26 5 8 7
Range 112 to 136 - 15 to -30 106 to 193 -7 to -24 51 to 84 7 to -18
p values refer to differences between atrial fibrillation or flutter versus sinus tachycardia. DAP = diastolic arterial pressure; HR = heart rate;
SAP = systolic arterial pressure.
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min developed frequent single ventricular extrasystoles that
disappeared after 5 minutes with continuation of esmolol.
These were asymptomatic and required no therapy.
Discussion
Prevention and treatment of postoperative atrial ar-
rhythmias. Although the mechanism of supraventricular
tachyarrhythmias early after open heart surgery is not well
understood , the frequent occurrence of such arrhythmias is
well documented (1-3,10-12) , Recognition of the value of
beta-adrenergic blockade to control ventricular response rates
and protect against paroxysmal supraventricular tachyar-
rhythmias dates from the mid 1960s (13-15), The value of
beta-adrenergic blocking therapy in the management of these
arrhythmias after cardiac surgery was also recognized early
(16), Because of difficulties in management, various pro-
phylactic regimens using either digoxin or beta-adrenergic
blockade (or both) have been studied. Digitalization, either
preoperative (I) or postoperative (17), has been shown to
be superior to no treatment in preventing postoperative
supraventricular tachyarrhythmias , The combination of di-
goxin and propranolol has also been advocated (2,18), as
well as propranolol alone (12,19,20). Patients receiving long-
term beta-adrenergic blocking therapy before surgery de-
serve special attention in this regard. Mounting clinical data
support the nonwithdrawal or early postoperative reinsti-
tution of beta-adrenergic blocking therapy to prevent the
effects of excessive postoperative adrenergic stimulation on
cardiac rhythm (3,4,12).
Potential value of esmolol. With the possibleexception
of patientson long-term preoperative beta-adrenergic block-
ing therapy, we, like others (21,22), have not observed
significant benefits of these variouspreventive measures and
instead have had to focus on acute "after the fact" man-
agement of postoperative supraventricular tachyarrhyth-
mias. Our findings suggest that esmolol may fulfill the reo
quirements of this unique setting. That is, it was rapidly
effective in controlling ventricular response rates due either
to atrial fibrillation or flutter or to sinus tachycardia and had
few adverse effects. Although hypotension was common,
it was well tolerated, particularly with the patient at bed
rest, and was frequently self-terminating or controlled with
intravenous fluid administration. In the two patients with
treatment-limiting hypotension, this side effect reversedex-
tremely rapidly when administration of the drug was
discontinued.
The standard therapies have one or more drawbacks not
seen with esmolol, Digoxin is not useful for control of sinus
tachycardia and, in contrast to serum drug levels, the onset
of its clinical effects is slow and sometimes, unpredictable.
Intravenous verapamil is useful, but its effects are short-
lived because it is not traditionally given by continuous
infusion; it also has no role in the treatment of sinus tachy-
cardia. Intravenous propranolol, also not usually given as
a continuous infusion, has limited safety because it lacks
cardioselectivity and its effects continue long after treatment
has stopped.
Combination drug therapy. Some patientsmay require
more prolonged oral beta-adrenergic blocking therapy for
sinus tachycardia. Although conversionto sinus rhythm was
not an expected outcome of our study, it did occur with
encouraging frequency (in 5 of the II patients not in sinus
rhythm) . In other patients with atrial fibrillation whose ar-
rhythmia is not converted to sinus rhythm, intravenous di-
goxin or type I antiarrhythmic medications may have to be
added during or shortly after the cessation of esmolol ther-
apy. Thus, the safety and efficacy of various combination
regimens is now under investigation.
Precautions. Potential drawbacks to the use of esmolol
should be pointed out. Because of its potency and rapidity
of onset of effect, selection of a small initial dose is rec-
ommended, and the infusion rate should be carefully con-
trolled, preferably witha volumetric intravenous pump. The
rapidity of drug clearance adds a safety factor should an
error of drug dose or concentration occur. In some patients
with sinus tachycardia, esmolol is likely to have only a
temporary effect because this arrhythmia may resume after
discontinuation of esmolol.
Conclusions. In reviewing the overall results with es-
molol for treatment of early postoperative supraventricular
tachyarrhythmias. several conclusions are warranted. One
can expect rapid and clinically important control of ven-
tricular response rates in this inherently unstable clinical
situation. These effects on heart rate should be seen at a
dose level of 200 JLg/kg per min or less, with little further
benefit above this level. Because of dose-dependent hypo-
tension, the optimal selection of patients would include those
whose blood pressure associated with their arrhythmia is
normal or only minimally depressed. Esmolol provides a
useful addition to, but not a replacement for, traditional
therapy .
We gratefully acknowledge the assistance of Douglas Allin. Marjorie Ray-
mond. Morgan Stewart and Helen Schamroth .
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